Cardiovascular diseases (CVDs) remain the leading global cause of morbidity and mortality, necessitating the development of novel therapeutic strategies. Conventional diagnostic and treatment methods often have limitations such as radiation exposure, complex procedures, and inadequate targeting, leading to suboptimal patient outcomes. In this context, nanotechnology has emerged as a transformative solution, offering advancements in regenerative medicine, targeted drug delivery, and precise imaging through the usage of nanobiomaterials. Therefore, this chapter explores the application of nanobiomaterials as nanotherapeutics for CVDs. It comprehensively provides an overview of CVDs, current therapeutic approaches, and the integration of nanotechnology in CVDs treatment. The role of nanobiomaterials in angiogenesis, tissue regeneration, drug delivery, and nanotheranostics for CVDs is also discussed in detail. Moreover, it reviews the use of nanotechnology in cardiovascular stents and implants, existing challenges, potential future advancements, and the overall impact of nanotherapeutics in CVDs management. In this context, advanced nanocarriers such as dendrimers, liposomes, and polymeric nanoparticles have demonstrated their aptitude to augment drug bioavailability while minimizing systemic toxicity. Furthermore, gold nanoparticles, superparamagnetic iron oxide nanoparticles, etc., have substantially improved imaging methods, enabling comprehensive and early disease identification. Nanotherapeutic approaches targeting atherosclerosis, myocardial infarction, restenosis, and other disorders have demonstrated significant prospects for boosting treatment efficacy and reducing stent placement hurdles. Despite these rises, issues associated with clinical translation, concerns about its adverse effects, and legal constraints urge further exploration. In summary, this chapter provides a detailed assessment of the role of nanobiomaterials in the management of CVDs, emphasizing their therapeutic potential, technological breakthroughs, and the difficulties that must be addressed before entirely adopting nanomedicine into clinical operation.